Dua anti-reflux stent relieves GI upper cancer distress

April 27, 2007

An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee. The study, using the anti-reflux biliary stent in patients with cancer of the pancreas or bile duct, appears in the May issue of Gastrointestinal Endoscopy journal.

This bile duct stent with the "Dua Anti-Reflux Valve," named after its inventor, was cleared for use by FDA last year. The Dua stent, for short, has also been approved for use in Europe and Canada.

The bile duct carries bile from the liver to the intestines. When this duct is obstructed from cancers of the pancreas, gallbladder, or bile duct, bile begins to backup resulting in jaundice, itching, fever, chills, other organ malfunctions and death. About 30,000 new patients with pancreatic cancer and 4,000 new cases of bile duct cancer are diagnosed in the United States each year, most frequently in older people.

Surgery to remove the tumors is generally the best treatment, but often the disease has progressed too far to consider surgery. Consequently, a stent, a tiny, hollow tube, is inserted using a minimally invasive procedure to help improve the passage of bile. However, these stents frequently clog requiring repeat procedures to replace the clogged stents. The exact mechanism that leads to stent clogging is not known. There is a possibility that clogging occurs from contents from the intestines backflowing (refluxing) into the stent.

The "Dua Anti-Reflux Valve" was initially developed to reduce reflux of stomach contents in patients with cancers of the esophagus. Resembling a windsock, it functions as a pressure-sensitive valve that closes when stomach pressure increases thereby preventing reflux. However, when the pressure builds beyond a certain point, the valve inverts allowing for belching or vomiting. By drinking one gulp of water, it reverts to its anti-reflux position.

The U.S. Food and Drug Administration cleared the "Dua Esophageal Stent" for use by patients with esophageal cancer in 2002. Using a similar windsock design, Dr. Dua modified the valve and attached it to the bile duct stent that closes whenever the pressure in the intestines increases so as to prevent backflow into the bile ducts.

Laboratory studies to evaluate the flow dynamics of this modified stent showed that its valve was effective in reducing backflow while maintaining its primary function, namely forward flow.

Dr. D.N. Reddy from the Asian Institute of Gastroenterology in Hyderabad, India, conducted a study on 60 consecutive patients in whom the bile duct was obstructed from cancer of the pancreas or the bile duct. He placed a standard biliary stent in 30 patients and the Dua stent in the remaining 30 patients. Addition of the anti-reflux valve on the Dua stent did not compromise the main function of the stent, i.e. bile drainage as both stents were equally effective in improving liver tests, and complication rates were similar.

The study showed that the stent with the Dua anti-reflux valve remained functional for a median of 145 days compared to 90 days in those with a standard stent. This resulted in fewer repeat endoscopies for stent changes in patients with the Dua stent. There were six patients in the anti-reflux stent group in whom the stent remained patent for six months and longer compared to only one such patient in the standard stent group.

"In patients with advanced cancers causing bile duct obstruction in whom life expectancy is limited, this difference may translate into fewer procedures to maintain bile duct patency. That means a better quality of life for these cancer patients," says Dr. Dua.

"Our next step is to do electron microscopic analysis of clogged standard and anti-reflux stents to evaluate the role of reflux of intestinal contents in stent clogging," Dua says. "We also hope to look at other uses for this type of stent."
-end-
EMBARGOED FOR RELEASE: Friday, April 27, 2007

Dr. Dua is associate professor of medicine at the Medical College and co-director of the Froedtert & Medical College GI Diagnostic and Therapeutic Laboratory. He is also the director of the Pancreatico-biliary Center at Froedtert, and chief of gastroenterology at the VA Medical Center in Milwaukee, both major teaching affiliates of the Medical College. He is a member of the Cancer Center and Digestive Disease Center at the Medical College.

Medical College of Wisconsin

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.